ArticleFrontiers in oncology2026
Laparoscopic radical proximal gastrectomy with double flap technique for early proximal gastric cancer: a prospective, phase II study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Proximal gastrectomy preserves gastric function but is limited by postoperative reflux. The double flap technique (DFT) offers an anti-reflux reconstruction, yet prospective evidence in China is lacking. Methods: This prospective, single-center phase II study evaluated the safety and efficacy of laparoscopic proximal gastrectomy with DFT (LPG-DFT) for early proximal gastric cancer. Primary outcome was reflux esophagitis at 12 months; secondary outcomes included perioperative results, nutrition, and quality of life (QoL). Results: Twenty patients underwent LPG-DFT without intraoperative complications or conversion. All achieved R0 resection, with a mean of 27.3 ± 8.9 lymph nodes harvested. No patient developed Los Angeles grade B or higher reflux at 12 months. Nutritional parameters showed only slight, nonsignificant declines. QoL scores decreased temporarily at 3 months but returned to baseline by 12 months. No major complications or mortality occurred. Conclusion: LPG-DFT is safe, effectively prevents reflux, and preserves nutrition and QoL, supporting its use in early proximal gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.